| 000 | 01674naa a2200229uu 4500 | ||
|---|---|---|---|
| 001 | 0122011051141 | ||
| 003 | OSt | ||
| 005 | 20190211174323.0 | ||
| 008 | 101220s2010 xx ||||gr |0|| 0 eng d | ||
| 100 | 1 |
_aMAOR, Moshe _96596 |
|
| 245 | 1 | 0 |
_aOrganizational reputation and jurisdictional claims : _bthe case of the U.S. food and drug administration |
| 260 |
_aMalden : _bWiley-Blackwell, _cjan. 2010 |
||
| 520 | 3 | _aWhen do regulatory agencies expand, following the emergence of novel technologies? This article presents a verbal model that suggests that a regulator is most likely to announce that it has statutory authority to regulate a novel technology when its reputation is at stake. This is most likely to occur when (1) new information becomes available to the regulator regarding the seriousness of the anticipated harm of a novel technology, or (2) a rival regulator attempts to formalize its regulatory authority or fails to do so although officially required to. A historicalinstitutional analysis of the temporal process leading to jurisdictional claims by the U.S. Food and Drug Administration over gene therapy, laboratory-developed complex diagnostic tests, human tissue transplants, and human cloning supports the model's prediction | |
| 650 | 4 |
_aTecnologia da Informação _911936 |
|
| 650 | 4 |
_aRegulação _912883 |
|
| 650 | 4 |
_aSaúde _912897 |
|
| 773 | 0 | 8 |
_tGovernance: An International Journal of Policy, Administration, and Institutions _g23, 1, p. 133-160 _dMalden : Wiley-Blackwell, jan. 2010 _xISSN 09521895 _w |
| 942 | _cS | ||
| 998 |
_a20101220 _b1105^b _cJaqueline |
||
| 998 |
_a20110131 _b1146^b _cKeicielle |
||
| 999 |
_aConvertido do Formato PHL _bPHL2MARC21 1.1 _c37869 _d37869 |
||
| 041 | _aeng | ||